Fab-glycosylated antibodies

摘要

The present invention pertains to a method for controlling the circulation half-life of antibodies by adjusting the amount of sialic acid in the carbohydrates attached to the Fab part of the antibodies. Furthermore, the present invention provides antibodies having an increased circulation half-life.

主权项

1. A method for treatment of cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of antibody composition comprising a chimeric or humanized anti-EGFR antibody or fragment or derivative thereof, comprising a heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2 and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO: 4, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 5and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 6; wherein the antibody comprises the following characteristics:
(i) the antibody comprises a glycosylation site present in the Fc part; (ii) in the composition at least 70% of the carbohydrates attached to the Fc part do not carry a fucose residue; (iii) in the composition at least 70% of the carbohydrates attached to the Fc part do not carry a sialic acid residue; (iv) in the composition at least 5% of the carbohydrates attached to the Fc part carry a bisecting acetylglucosamine residue; (v) in the composition at least 60% of the carbohydrates attached to the antibody carry at least one galactose residue; (vi) the carbohydrates attached to the antibody do not comprise a Galili epitope having the structure Galα(1→3)Galβ(1→4)GlcNAc; and (vii) the carbohydrates attached to the antibody do not comprise N-glycolylneuraminic acid (NeuGc) residues; (viii) optionally, in the composition at least 50% of the carbohydrates attached to the Fab part of the antibody or fragment or derivative thereof carry bisGlcNAc,wherein the patient is treated after failure of cetuximab treatment.